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The immunomodulating effects of interferons have led to 
their use in the treatment of a variety of illnesses, including 
cancer (1), and virally mediated infections, such as hepatitis 
(2). In addition, IFN has been given to immunosuppressed 
patients in an attempt to reconstitute the immune re~ponse 
to prevent viral infections such as CMV and herpes SImplex 
(3). Since CMV and viral hepatitis are potentially serious 
complications of renal transplantation (3, 4), the use of IFN 
for prophylaxis or treatment has been advocated in this set-
ting. However, the potential effects of giving an immuno-
modulator such as IFN to immunosuppressed transplant pa-
tients raises theoretical concerns about activation of immune 
responses and an increased risk of allograft rejection. 
Current immunosuppressive regimes for renal transplan-
tation include CsA or FK506 in combination with steroids 
and sometimes AZA. While the mechanisms of action of CsA 
and FK506 are not completely understood, these agents ap-
pear to inhibit T cell activation through binding to specific 
binding cellular proteins (immunophilins), thereby altering 
intracellular signaling pathways and ultimately inhibiting 
expression of IL-2 and other cytokines (5). Both CsA (6) and 
FK506 (7) may inhibit IFN production, and low levels of 
circulating IFN-a have been described in renal transplant 
recipients (8). Although IFN modulate the immune response-
both at the level of T cell activation (9) and antigen expres-
sion (10), the exact roles ofthese compounds in the immuno-
suppressive action of CsA and FK506 are not known. 
A number of studies have claimed efficacy of IFN-a prep-
arations in the treatment of chronic persistent hepatitis (2) 
and trials of IFN preparations for viral prophylaxis in renal 
transplant recipients have been reported (3, 11, 12). The 
results of such trials suggested a benefit of prophylaxis for 
viral infections (3, 11), but, at times, at the expense of in-
creased rejection (12). The complex issues involved in using 
IFN to treat hepatitis in a transplanted, immunosuppressed 
population prompted us to review our experience with IFN-a 
treatment in renal transplant patients. 
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CASE STUDIES 
Between June 1990 and April 1994, 11 renal transplant 
patients were treated with recombinant IFN-a at our center. 
Seven patients had undergone renal transplantation alone 
(group 1) and 4 patients had received renal transplants fol-
lowing orthotopic liver transplantation (group 2). The mean 
age of all patients was 38±3.8 years; there were 6 men and 5 
women. Renal transplantation had been performed 25±6 
months previously (range, 4-67 months). Seven patients had 
experienced early rejection during the first month after 
transplantation, but no patient had experienced more than 
one episode of rejection. The mean rejection-free interval 
before starting interferon was 28.4±5.7 months, and the 
baseline serum creatinine was 1.8±0.2 (range, 1.0-3.8) mg! 
100 ml. Patients received immunosuppression with either 
FK506 (6 patients) or CsA (4 patients) and prednisone. Five 
patients (1, 2, 4, 5, and 8) were also receiving AZA. One 
patient was on FK506 alone (patient 6). No patient had 
immunosuppression reduced at the initiation of IFN therapy. 
The indications for IFN therapy were persistently elevated 
liver function tests with seropositivity for hepatitis C in 10 
patients and surface antigenemia for hepatitis B in 1 patient 
(patient 2), with liver biopsy evidence of chronic hepatic 
inflammation. 
Kidney allograft function following induction of IFN-a 
therapy is shown in Table 1. The IFN dosage varied from 1.5 
to 5 X 106 U of rIFN -a given subcutaneously 3 times weekly 
and was planned as a 6-month course. Only 4 patients com-
pleted the entire course of therapy (mean treatment time, 
4.1±1.1 months). Six of 7 patients in group 1 and 1 of 4 
patients in group 2 experienced acute rejection at periods 
varying from 11 days to 8 months after initiation of IFN 
therapy (mean 2.9±0.8 months). Patient 2, who had persis-
tent hepatitis B, received 6 months of 5 x 106 U 3 times 
weekly and experienced rejection 6 weeks after completing 
the course of IFN-a. Renal function stabilized after a course 
of intravenous methylprednisone. Two months later he was 
retreated with IFN at 10x106 U 3 times weekly because of 
continuing deterioration of liver function. Within 2 weeks of 
restarting IFN therapy, the serum creatinine doubled (2.5 
mg/100 ml to 5 mg/100 ml) and did not fall despite discon-
tinuation of IFN and a steroid recycle. Two weeks later, 
dialysis was started and IFN therapy was reinstituted. The 
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TABLE 1. Patients, interferon treatment, and outcome 
Interval to Cr at -----Patient Age Baseline Cr Rejection-free INF dose (mg/100 ml) interval (rna) (3Xweekly) Mas Rx rejection rejEdion Therapy and outcome (rna) (mg/IOO ml) 
Group 1 ---------
1 51 1.8 19 2X106 1.5 1.5 li8 Steroid recycle,a hemodialysis 2 39 1.3 9 (a) 5X106 6 8 5.1 Steroid recycle, Cr stabilized (b) lOX106 0.5 0.5 7.5 Steroid recycle, hemodialysis 
3 33 3.8 56 3xI06 3 3 8.0 Steroid recycle, hemodialysis 
4 25 1.7 14 5X106 6 5 2.3 Steroid recycle, t INF to 3x106 Cr 
5 38 1.0 3X106 
stabilized X 1 mo, then hemodialysis 
66 2.5 2 3.0 Steroid recycle, i esA, hemodialysis 
6 34 1.2 21 5X106 0.3 0.3 3.7 Steroid recycle, IV FK, Cr required 
intermittent hemodialysis, stabilized 
at Cr 2.5 
7 25 2.4 36 (a)5X106 5 Stable renal function (Cr 2.0) at 36-mo 
follow-up 
(b) 3X106 5 
(c)5X106 3 
Group2 
8 37 1.8 9 3X106 2.5 2.5 6.1 Steroid recycle, IV FK, hemodialysis 
9 24 1.7 25 1.5X106 1.5 Discontinued for systemic side effects, 
renal function stable 
10 67 1.6 18 3X106 2.5 Still on Rx 
11 46 1.8 40 5XI06 6 Stable renal function 2-yr follow-up 
a An 8-day tapering course of prednisone was started at 200 mg daily. 
patient remained dialysis dependent until his death 6 
months later. 
Patient 4 was diagnosed with acute allograft rejection by 
renal biopsy following an increase in serum creatinine 5 
months into a course of 5xl06 U 3 times per week. He was 
treated with a steroid recycle and lowering of the IFN dosage 
to 3 x 106 U 3 times per week for the final month of his course. 
The serum creatinine level initially stabilized but subse-
quently rose, and dialysis was required 1 month after com-
pleting the course of IFN-a therapy. Patients 1, 3, 5, 6, and 8 
had IFN discontinued at the time of allograft rejection; all 
but patient 5 returned to dialysis within 1 month of the 
rejection episode. Patient 7 received 3 different courses of 
rIFN over a course of 24 months for persistent hepatitis 
C-related liver function abnormalities without ever experi-
encing rejection. This patient has stable allograft function 36 
months after treatment. 
The allograft histopathology of all 7 patients who experi-
enced graft dysfunction showed evidence of acute cellular 
rejection with interstitial cell infiltrates, hemorrhage, and 
tubulitis. Three patients (3, 4, and 8) had evidence of in-
creased endothelial reactivity and 2 others (patients 1 and 6) 
had focal necrosis of glomeruli, features that suggests vascu-
lar rejection. Of interest, 4 patients had new-onset protein-
uria varying from 1 to 5 g/day with minimal glomerular 
changes by light microscopy. 
DISCUSSION 
Six of 7 renal transplant recipients and 1 of 4 recipients of 
combined liver-renal transplants experienced acute deterio-
ration of allograft function associated with rIFN-a therapy. 
Although nephrotoxicity has been reported with IFN therapy 
(13), it is rare. Biopsy of our patients demonstrated cellular 
rejection, with some components of vascular rejection that 
occurred after long periods of graft stability. Rejection was 
not reversed by standard therapy and 6 ofthe 7 patients have 
returned to dialysis. 
Early reports of the use ofIFN-a for immunoprophylaxis of 
CMV infection used dosages similar to those used in our 
patients and were given over 3 months early after transplan·· 
tation. There was no associated increased graft loss or rejec-
tion episodes (3). These studies were carried out before rou-
tine use of CsA or FK506, but this experience has been 
essentially duplicated (11) in patients immunosuppressed 
with CsA. In contrast to these reports, high dose IFN therapy 
(36Xl06 U 3 times weekly) given to CsA-treated renal trans-
plant patients caused a marked increase in the occurrence of 
steroid-resistant acute rejections with vascular components 
(12). Although this experience suggested that the toxicity of 
IFN might be dose related, a recent placebo-controlled trial of 
IFN prophylaxis using doses similar to those used in our 
patients also demonstrated a significant increase in irrevers-
ible rejection in the IFN-treated patients (14). Thus, the 
relationship between IFN-a and allograft rejection can be 
seen irrespective of the dosage. 
Differences exist between the studies reviewed above and 
our experience. In all previous reports, IFN was given pro-
phylactically early after transplantation to patients with nor-
mal liver function. In our patients, a significant period of 
stable allograft function was followed by IFN-a therapy. 
However, recent experience shows that IFN-a may be quite 
safe when given to liver transplant recipients with active 
hepatocellular disease (15). Moreover, our own experience 
suggests that renal transplant patients with prior liver al-
lografts (patients 8, 9, and 10) may be more tolerant ofIFN-a 
treatment. More experience with IFN-a therapy in patients 
with different organ transplants is needed to determine 
whether this speculation is correct. 
Another possible factor involved in the precipitation of 
acute allograft rejection after IFN administration may be the 
----- ... -.------------------- - -_ .. _---_._-_ ... _ ... _---_._----
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preparation of IFN used. All reports of renal transplant dys-
function associated with IFN therapy involved the use of 
rIFN-a (12,14). Conversely, all reports of successful therapy 
with IFN have used preparations derived from leukocyte- or 
lymphocyte-stimulated cultures (3, 11). This raises the pos-
sibility that the purified recombinant preparation may actu-
ally have greater toxicity for allografts than preparations 
derived from stimulated cells. Alternatively, the latter prep-
arations may contain some protective factors. 
The mechanism of IFN-induced rejection in renal trans-
plants is not known, but the observed clinical cases suggest 
that suppression of IFN production may be a factor in avoid-
ing rejection in renal transplants. IFN-alJ3 has been shown to 
accelerate rejection in a model of heart transplantation (16), 
and it was suggested that this may be due to enhanced 
expression of class I antigens. IFN have been noted to en-
hance the expression of both class I and class II antigens (3). 
Our patients who experienced rejection had a mean 2.4±0.49 
class I mismatches (range 0-4) and 1.1±0.24 class II mis-
matches (range 0-2). Whatever the mechanism, our experi-
ence, and that of others, suggests that rIFN-a is associated 
with the development of resistant rejection in renal trans-
plant patients. 
REFERENCES 
1. Krawn SE. Interferons and interferon inducers in cancer treat-
ment. Semin Oncol 1986; 13: 207. 
2. Di Bisceglie AM, Martin P, Kassianides C, et aL Recombinant 
interferon alpha therapy for chronic hepatitis C: a randomized, 
double-blind, placebo-controlled triaL N Engl J Med 1989; 321 
(No. 22): 1506. 
3. Cheeseman SH, Rubin RR, Stewart JA, et aL Controlled clinical 
trial of prophylactic human-leukocyte interferon in renal 
transplantation: effects on cytomegalovirus and herpes sim-
plex virus infections. N Engl J Med 1979; 300 (No. 24): 1345. 
4. Rao KY, Anderson WR, Kasiske BL, Dahl DC. Value of liver 
biopsy in the evaluation and management of chronic liver 
disease in renal transplant recipients. Am J Med 1993; 94: 241. 
5. Furman DA, BurakoffSJ, Bierer BE. Immunophillins in protein 
folding and immunosuppression. FASEB J 1994; 8: 391. 
6. Reem GR, Cook LA. Gamma interferon synthesis by human 
thymocytes and T lymphocytes inhibited by cyclosporine A. 
Science 1983; 221: 63. 
7. Yoshimura N, Matsui S, Hamashima T, Oka T. Effect of a new 
immunosuppressive agent, FK506, on human lymphocyte re-
sponses in vitro. II. Inhibition of the production of IL-2 and 
-IFN, but not B cell-stimulating factor 2. Transplantation 
1984; 47: 36. 
8. Ambrus JL, Chadha KC, Anthone S, Athone R, Sayyid S. The 
alpha-interferon system in patients undergoing renal trans-
plantation and treated with cyclosporine and prednisone. Surg 
Gynecol Obstet 1993; 176: 588. 
9. Trinchieri D, Santoli D. Anti-viral activity induced by culturing 
lymphocytes with tumor-derived or virus transformed cells. 
Enhancement of human natural killer cell activity by culturing 
lymphocytes with turom-derived or virus-transformed cells: 
enhancement of human natural killer cell activity by inter-
feron and antagonistic inhibition or susceptibility of target 
cells to lysis. J Exp Med 1978; 147: 1314. 
10. DeMaeyer-Guignard J. Effects of interferon on cell mediated 
immunity as manifested by delayed hypersensitivity and al-
lograft rejection. In: Vilcek J, DeMaeyer E, eds. Interferon 2. 
Interferons and the immune system. Amsterdam: Elsevier Sci-
ence Publications, 1984: 133. 
11. Lui SF, Ali AA, Grund.y JE, Fernando ON, Griffiths PD, Sweny 
P. Double-blind, placebo-controlled trial of human lymphoblas-
toid interferon prophylaxis of cytomegalovirus infection in re-
nal transplant recipients. Nephrol Dial Transplant 1992; 7: 
1230. 
12. Kramer P, Kate FWJ, Bijnen AB, Jeekel J, Weimar W. Recom-
binant leucocyte interferon-a induces steroid-resistant acute 
vascular rejection episodes in renal transplant recipients. Lan-
cet 1984; 1: 989. 
13. Averbuch SD, Austin HA, Sherwin SA, Antonovych T, Bunn PA, 
Longo DL. Acute interstitial nephritis with the nephrotic syn-
drome following recombinant leukocyte a interferon therapy 
for mycosis fungoides. N Engl J Med 1984; 310 (No. 1): 32. 
14. Kovarik J, Mayer G, Pohanka E, et a1. Adverse effect oflow-dose 
prophylactic human recombinant leukocyte interferon-alpha 
treatment in renal transplant recipients: cytomegalovirus in-
fection prophylaxis leading to an increased. incidence of irre-
versible rejections. Transplantation 1988; 45 (No.2): 402. 
15. Gurakar A, Fagiuoli S, Hassanein T, et aL Role of early initiation 
of alpha-interferon (lFN) in the prevention of liver allograft 
reinfection with either HBV or HCV hepatitis. Gastroenterol-
ogy 1993; 104: 711A. 
16. Slater AD, Klein JB, Sonnenfeld G, Ogden LL, Gray LA. The 
effects of interferon-alphalbeta in a model of rat heart trans-
plantation. J Heart Lung Transplant 1992; 11: 975. 
Received 8 August 1994. 
Accepted 29 September 1994. 
